AASLD-INASL Joint Webinar: Advances in MASH Diagnosis and Treatment
Availability
Registration Required
Expires on Jun 13, 2026
Online Meeting
Jun 11, 2026 11:00 AM - 12:00 PM ET
Cost
$0.00
Credit Offered
No Credit Offered
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
The AASLD and INASL are excited to present their annual joint global webinar. This year's theme focuses on MASLD/MASH, where experts will discuss the evolving diagnostic landscape and treatment strategies for patients with MASH. The webinar is open to hepatologists, gastroenterologists, internists, hepatology associates, industry partners, and anyone else who may find this topic relevant.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.
Upon completion of this activity, participants should be able to:

  • Describe the evolving diagnostic landscape for MASH, including the implementation of non-invasive testing strategies.
  • Review the latest FDA-approved and emerging pharmacological therapies for MASH, focusing on the 2024-2025 approvals of resmetirom and semaglutide
  • Discuss integrated management of cardiometabolic comorbidities in MASH patients, including the role of incretin-based therapies (GLP-1 and dual agonists), cardiovascular risk reduction strategies, and hepatocellular carcinoma surveillance recommendations.
This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Ajay Duseja, MD, DM, FAASLD, FACG, FAMS, FSGEI, FISG, FINASL, Master-ISG
Nothing to Disclose


Arka De, MD, DM
Nothing to Disclose

Christina Awad, MD
Nothing to Disclose

Rohit Loomba, MD, MHSc, FAASLD
Employee/Owner: LipoNexus
Scientific Consultant/Advisor: Sagimet Biosciences, Aardvark, Altimmune, Arrowhead, AstraZeneca, Cascade , Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89bio, Takeda, Terns, Viking
Grant/Research Support: Arrowhead, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal,Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns

Shivaram P Singh, DM, FACG, AGAF, FRCP [Edin]., FAASLD
Nothing to Disclose

Shalimar, DM
Nothing to Disclose
Powered By